CClinicalTrials.gg
CompletedNCT02819167BCNUpdated Nov 20, 2017

Brain and Cognitive Reserve

An interventional study of neurologic and neuropsychological evaluation in Brain Ischemia, sponsored by Hospices Civils de Lyon. Completed at 1 site in France. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2017-11-20.

Sponsored by Hospices Civils de Lyon · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
70 Years and older
Sex
All
01

Study summary

Ischemic strokes are one of the leading causes of handicap and death in elderly people in France.

Cognitive reserve (CR) is an active model, defined as a function of lifetime intellectual activities and other environmental factors that explain differential susceptibility to functional impairment in the presence of pathology or other neurological insult. CR is estimated using variables for cognitive activity: years of education, professional status, socioeconomic status... Furthermore, brain reverse (BR) is a passive and quantitative model that depend on brain size and other quantitative aspects of the brain that explain differential susceptibility to functional impairment in the presence of pathology.

Firstly, volume and localization of ischemic strokes have a great impact on CR and BR due to brain injury. On the other hand, CR influences the severity and the expression of cognitive diseases.

The investigators realize a prospective study in order to assess the impact of CR and BR on cognitive prognosis after a right middle cerebral artery ischemic stroke in elderly patients.

02

Conditions studied

  • Brain Ischemia

Browse trials for

Keywords

  • ischemic stroke
  • brain reserve
  • cognitive reserve
  • cognitive prognosis
03

In context

Brain Ischemia

353 studies on the registry are indexed under Brain Ischemia; 69 are open to participants now.

This study's enrollment of 20 is below the median of 60 across 213 interventional studies indexed under Brain Ischemia.

Browse Brain Ischemia studies →

Lead sponsor

Hospices Civils de Lyon is the lead sponsor of 1,826 studies on the registry; 439 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
70 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • ≥70 years old
  • right middle cerebral artery ischemic stroke
  • hospitalized in neurovascular unit of Pierre Wertheimer hospital between January 2015 to January 2016

Exclusion criteria

Exclusion Criteria:

  • Contraindication for MRI
  • Hemorrhagic stroke
  • Aphasia
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Other
    neurologic and neuropsychological evaluation

    Other: neurologic and neuropsychological evaluation

Interventions

  • Otherneurologic and neuropsychological evaluation

    cognitive prognosis, cognitive reserve, brain volume will be studied on patients with scale, questionnaire, magnetic resonance imaging

06

What researchers measure

Primary outcomes

  1. evaluation of cognitive prognosis

    measure will be performed with the Mattis dementia rating scale

    Time frame: one year post Ischemic stroke

Secondary outcomes

  1. Volume of leucoencephalopathy

    measure will be performed with a MRI

    Time frame: one year post Ischemic stroke

  2. volume of hippocampic

    measure will be performed with a MRI

    Time frame: one year post Ischemic stroke

  3. brain injury

    measure will be performed with a MRI

    Time frame: one year post Ischemic stroke

  4. volume of ischemic stroke

    measure will be performed with a MRI

    Time frame: one year post Ischemic stroke

  5. evaluation of cognitive reserve

    measure will be performed with the Cognitive reserve index questionnaire

    Time frame: one year post Ischemic stroke

07

Study locations

1 site
  • Hôpital des Charpennes
    Lyon, France
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 20, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02819167
Lead sponsor
Hospices Civils de Lyon
Responsible party
Sponsor
First posted
Jun 30, 2016
Start date
May 26, 2016
Primary completion
Aug 2016
Completion
Aug 2016
Last update
Nov 20, 2017

Study contacts

Pierre Krolak Salmon, MD
principal investigator · Hospices Civils de Lyon

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion